Focused On-demand Library for CDAN1-interacting nuclease 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9Y2V0

UPID:

CDIN1_HUMAN

Alternative names:

Protein HH114

Alternative UPACC:

Q9Y2V0; B2RD87

Background:

CDAN1-interacting nuclease 1, also known as Protein HH114, plays a pivotal role in erythroid cell differentiation. This protein's involvement in the maturation and development of red blood cells underscores its importance in hematopoiesis. The unique structural features of CDAN1-interacting nuclease 1, including its interaction with other cellular components, make it a key player in the maintenance of erythrocyte integrity.

Therapeutic significance:

The association of CDAN1-interacting nuclease 1 with congenital dyserythropoietic anemia, 1B, a disorder marked by ineffective erythropoiesis and macrocytic anemia, highlights its therapeutic potential. Targeting the pathways involving this protein could lead to innovative treatments for this and related blood disorders, offering hope for patients suffering from these conditions.